Thymosin Alpha-1

Thymosin Alpha-1 Peptide
Thymosin Alpha-1 (Tα1) is a synthetic peptide originally isolated from thymic tissue and composed of 28 amino acids. It is not glycosylated and is classified as an immunomodulatory peptide. Research suggests that Tα1 may support immune system regulation by interacting with innate and adaptive pathways. It has been studied for its potential role in enhancing T-cell activity, stimulating dendritic cell maturation, and modulating cytokine release.

Overview
Thymosin Alpha-1 is hypothesized to act through binding to toll-like receptors (TLRs) on antigen-presenting cells, possibly leading to increased production of interleukin-2 (IL-2) and interferon-gamma (IFN-γ). These cytokines are thought to play a central role in adaptive immunity by promoting the proliferation and activity of cytotoxic T lymphocytes and natural killer cells.

Investigations suggest that Tα1 may enhance antigen presentation by dendritic cells, potentially improving immune recognition. Experimental findings also indicate that the peptide could promote a balance between pro-inflammatory and anti-inflammatory cytokines, thereby helping to maintain immune homeostasis.

Chemical Makeup

Molecular Formula: C129H215N33O55
Molecular Weight: 3108.35 g/mol
Other Known Titles: Thymalfasin

Research and Clinical Studies

Thymosin Alpha-1 and Immune Regulation
Studies report that Tα1 can enhance proliferation and function of CD4+ and CD8+ T cells, increase NK cell cytotoxicity, and modulate dendritic cell maturation. These effects are associated with improved antigen presentation and a coordinated cytokine milieu consistent with balanced immune responsiveness.

Thymosin Alpha-1 and Viral Models
In chronic viral infection models (including hepatitis B and C), Tα1 has been investigated as an adjunct to standard regimens. Findings include improved interferon signaling dynamics and more normalized immune profiles, with reports of enhanced virologic responses when combined with conventional therapies.

Thymosin Alpha-1 and Oncology
Tα1 has been explored as an immune adjuvant in oncology settings, where it may improve tumor antigen recognition and complement checkpoint inhibition or chemotherapy by reducing tumor-induced immune dysfunction and supporting T-cell–mediated surveillance.

Thymosin Alpha-1 and Sepsis / Critical Illness
Experimental and clinical data suggest that Tα1 may mitigate immune dysregulation in sepsis by limiting lymphocyte apoptosis and recalibrating pro-/anti-inflammatory signaling, potentially contributing to restoration of immune homeostasis during critical illness.

Thymosin Alpha-1 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.

References

1. Garaci E, Pica F, Serafino A, et al. Thymosin α1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci. 2012;1269:26–32. https://doi.org/10.1111/j.1749-6632.2012.06735.x
   
2. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103(11):4232–4239. https://doi.org/10.1182/blood-2003-09-3099
   
3. King R, Tuthill C. Immune modulation with thymosin alpha 1 treatment. Vitam Horm. 2016;102:151–178. https://doi.org/10.1016/bs.vh.2016.04.007
   
4. Ciabattini A, Pettini E, Medaglini D. Thymosin alpha 1 as immune adjuvant in therapeutic vaccines. Expert Opin Biol Ther. 2018;18(sup1):61–67. https://doi.org/10.1080/14712598.2018.1518214
   
5. Sherman KE, Sjogren MH, Creager RL, et al. Thymosin α1 and interferon for chronic hepatitis C: a randomized, placebo-controlled trial. Hepatology. 1998;27(4):1128–1135. https://pubmed.ncbi.nlm.nih.gov/9537447/
   
6. Cordero OJ, Salgado FJ, Vinuela JE, et al. Immune activation by thymosin alpha 1 in subjects with immunodeficiency. Int Immunopharmacol. 2001;1(12):1949–1959. https://doi.org/10.1016/S1567-5769(01)00139-1
   
7. Costantini C, Bellet MM, Pariano M, et al. A reappraisal of thymosin α1 in cancer therapy. Front Oncol. 2019;9:873. https://doi.org/10.3389/fonc.2019.00873
   
8. Matteucci C, Grelli S, De Smaele E, et al. Thymosin alpha 1 and immune response: new insights and potential applications. Future Sci OA. 2017;3(3):FSO236. https://doi.org/10.4155/fsoa-2016-0089
   
9. ClinicalTrials.gov. Thymosin Alpha 1 in Immunodeficiency. https://clinicaltrials.gov/ct2/show/NCT00586981
   
10. Fabris N, Garaci E. Thymosin alpha 1 in immunotherapy. Methods Find Exp Clin Pharmacol. 1991;13(3):167–176. https://pubmed.ncbi.nlm.nih.gov/1886031/